华兰生物: 关于董事会完成换届选举暨聘任高级管理人员等相关人员的公告

Board Restructuring - The company held a board meeting on July 8, 2025, to elect a new board of directors, which will serve a term of three years from the date of approval by the shareholders' meeting [1][2] - The newly elected board includes non-independent directors An Kang, Fan Bei, An Wenqi, An Wenjue, and Pan Ruowen, as well as independent directors Su Zhiguo, Wang Yunlong, and Liu Wanli [1][2] Management Appointments - Fan Bei was appointed as the General Manager, and Xie Junmin was appointed as the Secretary of the Board [3] - Other key appointments include Ma Xiaowei as Executive Vice General Manager, Zhang Baoxian, Chen Zhengyue, and Liu Jun as Vice General Managers, and Xie Junmin as Chief Financial Officer [3] Committee Structure - An Kang was elected as the Chairman of the Board, and various committees were formed, including the Strategy Committee, Compensation and Assessment Committee, Nomination Committee, and Audit Committee [2] - Independent directors constitute more than half of the members in the Audit, Nomination, and Compensation Committees, with Liu Wanli serving as the chair of the Audit Committee [2] Securities Affairs - Lou Yuancheng was appointed as the Securities Affairs Representative to assist the Secretary of the Board [3]